Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation

被引:13
|
作者
Roman-Garcia, Sara [1 ]
Merino-Cortes, Sara V. [1 ]
Gardeta, Sofia R. [1 ]
de Bruijn, Marjolein J. W. [2 ]
Hendriks, Rudi W. [2 ]
Carrasco, Yolanda R. [1 ]
机构
[1] CSIC, CNB, Dept Immunol & Oncol, Cell Dynam Lab B, Madrid, Spain
[2] Erasmus Univ, Dept Pulm Med, Med Ctr, Rotterdam, Netherlands
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
关键词
B cells; Btk; immune synapse; actin cytoskeleton; shuttling/scaffold; kinase; cell activation; PROTEIN-DEFICIENCY; ACTIVATION; BTK; ADHESION; ANTIGEN; ACTIN; LYMPHOCYTES; DYNAMICS; TEC; EXPRESSION;
D O I
10.3389/fimmu.2018.02027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bruton's tyrosine kinase (Btk) has a key role in the signaling pathways of receptors essential for the B lymphocyte response. Given its implication in B cell-related immunodeficiencies, leukemias/lymphomas and autoimmunity, Btk is studied intensely and is a target for therapy. Here, using primary B cells from distinct mouse models and the pharmacological inhibitors ibrutinib and acalabrutinib, we report distinct roles for Btk in antigen-triggered immune synapse (IS) formation. Btk recruitment to the plasma membrane regulates the B cell ability to trigger IS formation as well as its appropriate molecular assembly; Btk shuttling/scaffold activities seem more relevant than the kinase function on that. Btk-kinase activity controls antigen accumulation at the IS through the PLC gamma 2/Ca2+ axis. Impaired Btk membrane-recruitment or kinase function likewise alters antigen-triggered microtubule-organizing center (MTOC) polarization to the IS, B cell activation and proliferation. Data also show that, for B cell function, IS architecture is as important as the quantity of antigen that accumulates at the synapse.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Targeting Bruton's tyrosine kinase in B cell malignancies
    Rudi W. Hendriks
    Saravanan Yuvaraj
    Laurens P. Kil
    Nature Reviews Cancer, 2014, 14 : 219 - 232
  • [2] Targeting Bruton's tyrosine kinase in B cell malignancies
    Hendriks, Rudi W.
    Yuvaraj, Saravanan
    Kil, Laurens P.
    NATURE REVIEWS CANCER, 2014, 14 (04) : 219 - 232
  • [3] Bruton's tyrosine kinase is essential for human B cell tolerance
    Ng, YS
    Wardemann, H
    Chelnis, J
    Cunningham-Rundles, C
    Meffre, E
    JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 200 (07): : 927 - 934
  • [4] The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
    Rip, Jasper
    Van Der Ploeg, Esmee K.
    Hendriks, Rudi W.
    Corneth, Odilia B. J.
    CRITICAL REVIEWS IN IMMUNOLOGY, 2018, 38 (01) : 91 - 136
  • [5] Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus
    Satterthwaite, Anne B.
    FRONTIERS IN IMMUNOLOGY, 2018, 8
  • [6] Bruton's tyrosine kinase couples NF-κB to the B cell receptor
    Petro, JB
    Rahman, SMJ
    Khan, WN
    FASEB JOURNAL, 2000, 14 (06): : A929 - A929
  • [7] Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies
    Gayko, Urte
    Fung, Mann
    Clow, Fong
    Sun, Steven
    Faust, Elizabeth
    Price, Samiyeh
    James, Danelle
    Doyle, Margaret
    Bari, Samina
    Zhuang, Sen Hong
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN 2014, 2015, 1358 : 82 - 94
  • [8] Lysine Acetylation Regulates Bruton's Tyrosine Kinase in B Cell Activation
    Liu, Zhijian
    Mai, Antonello
    Sun, Jian
    JOURNAL OF IMMUNOLOGY, 2010, 184 (01): : 244 - 254
  • [9] Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells
    Feldhahn, N
    Rio, P
    Soh, BNB
    Liedtke, S
    Sprangers, M
    Klein, F
    Wernet, P
    Jumaa, H
    Hofmann, WK
    Hanenberg, H
    Rowley, JD
    Müschen, M
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (37) : 13266 - 13271
  • [10] Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
    Caspar da Cunha-Bang
    Carsten Utoft Niemann
    Drugs, 2018, 78 : 1653 - 1663